Study of T Cell Phenotype Activation Pathway in Human Alcoholic Liver Disease
NCT ID: NCT00610597
Last Updated: 2008-02-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
49 participants
OBSERVATIONAL
2005-01-31
2008-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Immune Cell Dysfunction in Severe Alcoholic Hepatitis
NCT02275195
Protective Immune Mechanisms in Alcoholic Hepatitis
NCT01918462
Single Cell Landscape of HBV-related Acute-on-chronic Liver Failure Patients
NCT06865859
Prospective Studies on Immunopathogenesis of Liver Fibrosis
NCT04943978
Albumin Modifications as Early Biomarkers of Chronic Liver Diseases
NCT06318949
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
alcoholic liver disease
No interventions assigned to this group
2
chronic hepatitis C virus infection
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Alcohol excess intake and clinical liver cirrhosis
* chronic hepatitis C virus infection and suspected liver disease
* chronic hepatitis C virus infection and clinical liver cirrhosis
Exclusion Criteria
* immunosuppressive treatment
* other causes of liver disease
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Erasme University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Erasme University Hospital
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Arnaud Lemmers, MD
Role: PRINCIPAL_INVESTIGATOR
Erasme Hospital, Gastroenterology Dpt
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hopital Erasme - Dpt of Gastroenterology
Brussels, , Belgium
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Lemmers A, Moreno C, Gustot T, Marechal R, Degre D, Demetter P, de Nadai P, Geerts A, Quertinmont E, Vercruysse V, Le Moine O, Deviere J. The interleukin-17 pathway is involved in human alcoholic liver disease. Hepatology. 2009 Feb;49(2):646-57. doi: 10.1002/hep.22680.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AL-ALD
Identifier Type: -
Identifier Source: secondary_id
AL-ALD
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.